Sign up to access historical data
Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$7M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$127M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Klima Thomas J | Jun 3, 2024 | Sell | 3,834 | $0.9719 | $3,700 |
| Obenshain Andrew | Mar 4, 2024 | Sell | 6,095 | $1.5276 | $9,300 |
| Klima Thomas J | Mar 4, 2024 | Sell | 4,573 | $1.5276 | $7,000 |
| Colvin Richard A | Mar 1, 2024 | Sell | 6,770 | $1.5276 | $10,000 |
| Klima Thomas J | Feb 5, 2024 | Sell | 2,714 | $0.9025 | $2,400 |
| Vittiglio Joseph | Feb 5, 2024 | Sell | 5,217 | $0.9025 | $4,700 |
| Obenshain Andrew | Feb 5, 2024 | Sell | 1,879 | $0.9025 | $1,700 |
| Obenshain Andrew | Jan 5, 2024 | Sell | 3,162 | $1.4294 | $4,500 |
| Colvin Richard A | Jan 5, 2024 | Sell | 597 | $1.415 | $840 |
| Krawtschuk Christopher | Dec 6, 2023 | Sell | 4,526 | $4.5155 | $20,000 |
| Obenshain Andrew | Nov 3, 2023 | Sell | 807 | $3.1659 | $2,600 |
| Colvin Richard A | Nov 2, 2023 | Sell | 2,343 | $2.9769 | $7,000 |
| Klima Thomas J | Sep 5, 2023 | Sell | 922 | $3.7886 | $3,500 |
| Obenshain Andrew | Aug 10, 2023 | Sell | 16,929 | $3.5416 | $60,000 |
| Klima Thomas J | Jun 2, 2023 | Sell | 4,130 | $3.499 | $14,000 |
| Obenshain Andrew | Jan 11, 2023 | Sell | 3,178 | $7.8043 | $25,000 |
| Leschly Nick | Jan 11, 2023 | Sell | 4,290 | $7.8043 | $33,000 |
| Colvin Richard A | Jan 11, 2023 | Sell | 557 | $7.8043 | $4,300 |
| Obenshain Andrew | Nov 4, 2022 | Sell | 1,263 | $6.4137 | $8,100 |
| Colvin Richard A | Nov 4, 2022 | Sell | 218 | $6.4137 | $1,400 |
| Leiderman Elisabeth | Oct 17, 2022 | Sell | 1,004 | $6.4643 | $6,500 |
What's the latest insider transaction for Bluebird bio?
The most recent insider transaction for Bluebird bio was conducted by Klima Thomas J, who sold 3,834 shares on June 3, 2024 at a price of $0.97 per share.
Which insider has sold the most BLUE stock over the last two years?
Obenshain Andrew has sold the most BLUE stock in the last 2 years, with a total value of $110,000.
What is the total value of insider transactions for Bluebird bio (BLUE) in the last 2 years?
The total value of insider transactions for Bluebird bio in the last 2 years is negative, amounting to -$230,000. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Bluebird bio's market confidence?
Over the last 2 years, insider transactions for Bluebird bio have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
